Literature DB >> 31043439

Impact of Lipid Partitioning on the Design, Analysis, and Interpretation of Microsomal Time-Dependent Inactivation.

Jaydeep Yadav1, Ken Korzekwa1, Swati Nagar2.   

Abstract

Nonspecific drug partitioning into microsomal membranes must be considered for in vitro-in vivo correlations. This work evaluated the effect of including lipid partitioning in the analysis of complex TDI kinetics with numerical methods. The covariance between lipid partitioning and multiple inhibitor binding was evaluated. Simulations were performed to test the impact of lipid partitioning on the interpretation of TDI kinetics, and experimental TDI datasets for paroxetine (PAR) and itraconazole (ITZ) were modeled. For most kinetic schemes, modeling lipid partitioning results in statistically better fits. For MM-IL simulations (KI,u = 0.1 µM, kinact = 0.1 minute-1), concurrent modeling of lipid partitioning for an fumic range (0.01, 0.1, and 0.5) resulted in better fits compared with post hoc correction (AICc: -526 vs. -496, -579 vs. -499, and -636 vs. -579, respectively). Similar results were obtained with EII-IL. Lipid partitioning may be misinterpreted as double binding, leading to incorrect parameter estimates. For the MM-IL datasets, when fumic = 0.02, MM-IL, and EII model fits were indistinguishable (δAICc = 3). For less partitioned datasets (fumic = 0.1 or 0.5), the inclusion of partitioning resulted in better models. The inclusion of lipid partitioning can lead to markedly different estimates of KI,u and kinact A reasonable alternate experimental design is nondilution TDI assays, with post hoc fumic incorporation. The best fit models for PAR (MIC-M-IL) and ITZ (MIC-EII-M-IL and MIC-EII-M-Seq-IL) were consistent with their reported mechanism and kinetics. Overall, experimental fumic values should be concurrently incorporated into TDI models with complex kinetics, when dilution protocols are used.
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31043439      PMCID: PMC6556519          DOI: 10.1124/dmd.118.085969

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  52 in total

1.  Commentary: nonspecific protein binding versus membrane partitioning: it is not just semantics.

Authors:  Swati Nagar; Ken Korzekwa
Journal:  Drug Metab Dispos       Date:  2012-06-18       Impact factor: 3.922

2.  Visible spectra of type II cytochrome P450-drug complexes: evidence that "incomplete" heme coordination is common.

Authors:  Charles W Locuson; J Matthew Hutzler; Timothy S Tracy
Journal:  Drug Metab Dispos       Date:  2007-01-24       Impact factor: 3.922

3.  The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America.

Authors:  Scott W Grimm; Heidi J Einolf; Steven D Hall; Kan He; Heng-Keang Lim; Kah-Hiing John Ling; Chuang Lu; Amin A Nomeir; Eleanore Seibert; Konstantine W Skordos; George R Tonn; Robert Van Horn; Regina W Wang; Y Nancy Wong; Tian J Yang; R Scott Obach
Journal:  Drug Metab Dispos       Date:  2009-04-09       Impact factor: 3.922

4.  An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes.

Authors:  Andrew Parkinson; Faraz Kazmi; David B Buckley; Phyllis Yerino; Brandy L Paris; Jeff Holsapple; Paul Toren; Steve M Otradovec; Brian W Ogilvie
Journal:  Drug Metab Dispos       Date:  2011-04-27       Impact factor: 3.922

Review 5.  A novel type of allosteric regulation: functional cooperativity in monomeric proteins.

Authors:  Ilia G Denisov; Stephen G Sligar
Journal:  Arch Biochem Biophys       Date:  2012-01-08       Impact factor: 4.013

6.  Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions.

Authors:  M Ishigam; M Uchiyama; T Kondo; H Iwabuchi; S Inoue; W Takasaki; T Ikeda; T Komai; K Ito; Y Sugiyama
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

7.  Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition.

Authors:  Aleksandra Galetin; Howard Burt; Laura Gibbons; J Brian Houston
Journal:  Drug Metab Dispos       Date:  2005-10-12       Impact factor: 3.922

8.  Numerical analysis of time dependent inhibition kinetics: comparison between rat liver microsomes and rat hepatocyte data for mechanistic model fitting.

Authors:  Chuong Pham; Swati Nagar; Ken Korzekwa
Journal:  Xenobiotica       Date:  2017-06-23       Impact factor: 1.908

9.  Role of itraconazole metabolites in CYP3A4 inhibition.

Authors:  Nina Isoherranen; Kent L Kunze; Kyle E Allen; Wendel L Nelson; Kenneth E Thummel
Journal:  Drug Metab Dispos       Date:  2004-07-08       Impact factor: 3.922

10.  Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.

Authors:  Jaydeep Yadav; Ken Korzekwa; Swati Nagar
Journal:  Mol Pharm       Date:  2018-04-10       Impact factor: 4.939

View more
  6 in total

1.  Numerical Methods for Modeling Enzyme Kinetics.

Authors:  Jaydeep Yadav; Ken Korzekwa; Swati Nagar
Journal:  Methods Mol Biol       Date:  2021

Review 2.  Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.

Authors:  Jaydeep Yadav; Erickson Paragas; Ken Korzekwa; Swati Nagar
Journal:  Pharmacol Ther       Date:  2019-12-11       Impact factor: 12.310

3.  Mechanisms of Herb-Drug Interactions Involving Cinnamon and CYP2A6: Focus on Time-Dependent Inhibition by Cinnamaldehyde and 2-Methoxycinnamaldehyde.

Authors:  Michael J Espiritu; Justin Chen; Jaydeep Yadav; Michael Larkin; Robert D Pelletier; Jeannine M Chan; Jeevan B Gc; Senthil Natesan; John P Harrelson
Journal:  Drug Metab Dispos       Date:  2020-08-12       Impact factor: 3.922

4.  Proliposomes for oral delivery of total biflavonoids extract from Selaginella doederleinii: formulation development, optimization, and in vitro-in vivo characterization.

Authors:  Bing Chen; Xuewen Wang; Dan Lin; Dafen Xu; Shaoguang Li; Jianyong Huang; Shaohuang Weng; Zhen Lin; Yanjie Zheng; Hong Yao; Xinhua Lin
Journal:  Int J Nanomedicine       Date:  2019-08-20

5.  Improved solubility, dissolution rate, and oral bioavailability of main biflavonoids from Selaginella doederleinii extract by amorphous solid dispersion.

Authors:  Bing Chen; Xuewen Wang; Yanyan Zhang; Kangping Huang; Hao Liu; Dafen Xu; Shaoguang Li; Qicai Liu; Jianyong Huang; Hong Yao; Xinhua Lin
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

6.  Using partition analysis as a facile method to derive net clearances.

Authors:  Ken Korzekwa; Jaydeep Yadav; Swati Nagar
Journal:  Clin Transl Sci       Date:  2022-06-02       Impact factor: 4.438

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.